BlackRock Inc. Acquires Shares of 4,123,822 Dianthus Therapeutics, Inc. $DNTH

Key Points

• BlackRock acquired 4.12 million Dianthus Therapeutics shares worth approximately $402 million, giving it a 7.54% stake. Institutional investors collectively own 47.53% of the company.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $124.27; individual targets reached as high as $131.
• DNTH shares opened at $112.11 after rising 1.9%, while the company reported a quarterly loss of $0.90 per share—worse than expectations—and insiders sold roughly $29.6 million of stock over the past three months.

BlackRock Inc. acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,123,822 shares of the company's stock, valued at approximately $401,990,000. BlackRock Inc. owned about 7.54% of Dianthus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. American Century Companies Inc. grew its stake in Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company's stock worth $1,009,000 after buying an additional 6,323 shares during the last quarter. Invesco Ltd. grew its stake in Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company's stock worth $390,000 after buying an additional 4,962 shares during the last quarter. Alliancebernstein L.P. increased its position in Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock worth $21,887,000 after buying an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics during the second quarter worth approximately $27,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Analyst Ratings Changes

DNTH has been the subject of a number of research reports. TD Cowen reiterated a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Raymond James Financial restated a "strong-buy" rating and set a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Truist Financial lifted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $124.27.

Dianthus Therapeutics Stock Up 1.9%

Shares of DNTH stock opened at $112.11 on Wednesday. The stock's 50-day moving average price is $101.97 and its 200 day moving average price is $86.07. The stock has a market capitalization of $6.13 billion, a PE ratio of -27.01 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 52-week low of $22.81 and a 52-week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In related news, Director Simon Read sold 2,778 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares of the company's stock, valued at $326,553.90. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 287,084 shares of company stock valued at $29,615,923. Corporate insiders own 3.02% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source